Thromboprophylaxis in Lower Limb Immobilisation
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age16+
SponsorQueen Mary University of London
About this trial
The goal of this clinical trial is to find out the clinical and cost effectiveness of Thromboprophylaxis in participants who have been placed in a plaster cast or splint after injury.
The main questions it aims to answer are:
* whether giving tablets to people at high risks of clots after a leg injury is as good as injections (standard care) * whether giving any medication after a leg injury is better than standard care (advice only) for people at low risk of clots.
Participants will be assessed to be high risk (TiLLI High) or low risk (TiLLI Low). People who are at high risk of clots will have either tablets or injections to reduce their risk. People at low risk will receive tablets, injections or no medication.
Drug treatments will be provided for the duration of immobilisation or up to 42 days (whichever is earlier), in accordance with current NICE guidelines. The participants will be followed up for 90 days following randomisation.
Eligibility criteria
Qualifiers
Age >/= 16 years
Placed in temporary lower limb immobilisation (rigid cast or brace) as a result an injury that occurred within the last 7 calendar days
Disqualifiers
Hospital admission is required direct from the emergency department, minor injuries unit, or fracture clinic setting with an expected length of stay >2 calendar days.
Absolute contraindication or known hypersensitivity to anticoagulants, including history of end stage renal failure (eGFR <20ml/min/1.73m2), hepatic failure or use of concomitant systemic treatment with azole-antimycotics (such as ketoconazole, itraconazole, voriconazole and posaconazole), HIV protease inhibitors (e.g. ritonavir) or active substances strongly inhibiting elimination pathways such as CYP3A4 or P-gp (such as clarithromycin, erythromycin or dronaderone) or a history of heparin induced thrombocytopenia.
Pregnancy, actively seeking conception, or active breastfeeding.
Preceding use of anticoagulant treatment for >3 calendar days at prophylactic or therapeutic dose.
Trial design
Treatments tested in this trial
- Rivaroxaban
- Apixaban
- Enoxaparin Injectable Solution
- Tinzaparin Injectable Solution
- Dalteparin Injectable Solution
- Fondaparinux Injectable Product
Treatment groups
10,044 Participants
are divided into 5 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov